International Stem Cell (OTCPK:ISCO) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
International Stem Cell EBITDA Margin % Related Terms
International Stem Cell EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISCO vs ONCO, VRAX, LYRA: EBITDA Margin % Comparison
For the Biotechnology subindustry, International Stem Cell's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
International Stem Cell EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, International Stem Cell's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where International Stem Cell's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
International Stem Cell (ISCO) has a EBITDA Margin % of -6.52% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on International Stem Cell and its competitors. According to the industry distribution chart, International Stem Cell ranks #307 out of 945 companies in the Biotechnology industry, placing it in the top 32.5%.
Is International Stem Cell's EBITDA Margin % too high?
International Stem Cell's current EBITDA Margin % is -6.52%. Based on the distribution chart, International Stem Cell ranks #307 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, International Stem Cell has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does International Stem Cell's EBITDA Margin % compare to ONCO and VRAX?
According to the Biotechnology industry distribution chart, International Stem Cell ranks #307 out of 945 companies for EBITDA Margin %. This puts International Stem Cell in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on International Stem Cell and its competitors. International Stem Cell's current EBITDA Margin % is -6.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Stem Cell stock overvalued right now?
Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.18 — trading 37% above its estimated fair value. The current EBITDA Margin % is -6.52%. International Stem Cell's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For International Stem Cell (ISCO), the current EBITDA Margin % is -6.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is International Stem Cell (ISCO) Overvalued in 2026?
Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued.
The current stock price of $0.18 is trading 37% above its estimated GF Value™ of $0.13.
GuruFocus considers International Stem Cell to be Significantly Overvalued.
Key valuation signals for ISCO:
EBITDA Margin %: -6.52%
GF Value™: $0.13 vs. price of $0.18 (37% above fair value)
No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
28GF Score
Get the complete analysis for ISCO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISCO has been successfully added to your 
